Drug Overview
Ninlaro (ixazomib; Takeda) reversibly inhibits the 20S proteasome, resulting in the accumulation of proteins and eventually leading to the activation of apoptotic pathways.
Preclinical studies suggest that Ninlaro demonstrates a stronger anti-tumor effect than Velcade (bortezomib; Takeda/Johnson & Johnson).
Ninlaro (ixazomib; Takeda) reversibly inhibits the 20S proteasome, resulting in the accumulation of proteins and eventually leading to the activation of apoptotic pathways.
Preclinical studies suggest that Ninlaro demonstrates a stronger anti-tumor effect than Velcade (bortezomib; Takeda/Johnson & Johnson).
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES